title: Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction.
abstract: BACKGROUND
  Salivary and lacrimal side effects of radioiodine therapy have been carefully described. However, nasal side effects are rarely described. The objective of this study was to document the frequency of nasal side effects in comparison to the already well-documented lacrimal side effects and to determine contributing risk factors.
  
  
  METHODS
  A retrospective review of the medical records of 807 patients with differentiated thyroid cancer who received care at an academic medical center was conducted. Four hundred eleven patients who received treatment with radioactive iodine (RAI) were identified and included in the analysis. The frequency of both nasal and lacrimal side effects was ascertained. Factors that may have contributed to patients sustaining nasal damage after RAI therapy were also documented. These factors included radioactive iodine dose, method of preparation for receiving RAI therapy, and patient characteristics.
  
  
  RESULTS
  The mean dose of RAI administered was 109 mCi. Forty-three patients (10.5%) and 40 patients (9.7%) developed nasal and lacrimal side effects, respectively, following RAI treatment. The mean time of onset of nasal symptoms was 11 days, compared with 10 months for lacrimal symptoms. Radioiodine dose and body mass index were significantly positively and negatively correlated, respectively, with sustaining nasal side effects (p values of 0.04 and 0.01, respectively). Similarly, both RAI dose and body mass index were significantly correlated, positively and negatively, respectively, with sustaining lacrimal side effects (p values of 0.02 and 0.01). Preparation for treatment using a withdrawal protocol was associated with increased risk of both nasal and lacrimal side effects, compared with a recombinant human thyrotropin (rhTSH) protocol (p values of <0.01 and 0.01). The odds ratios (95% confidence interval [CI]) for nasal and lacrimal side effects with recombinant rhTSH preparation were 0.22 [0.11-0.44] and 0.37 [0.18-0.76], respectively. Instructions to maintain adequate hydration and development of lacrimal symptoms were only associated with nasal symptoms in unadjusted analyses.
  
  
  CONCLUSIONS
  Both nasal and lacrimal dysfunction occurred at an approximately 10% frequency. Although it cannot be determined whether acute nasal side effects are followed by long-term ramifications, these consequences of RAI could potentially add to the reasons to carefully evaluate the benefits and risks of RAI therapy on an individual basis.
authors.affiliation: Division of Endocrinology, Georgetown University , Washington, DC.
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Jonklaas
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D007766:Lacrimal Apparatus Diseases / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009668:Nose Diseases / Q000209:etiology*; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000532:radiotherapy*
chemical_list: D007457:Iodine Radioisotopes
references.citation: Clin Nucl Med. 1996 Oct;21(10):780-2
references.pmid: 8896926
references.citation: N Engl J Med. 2012 May 3;366(18):1663-73
references.pmid: 22551127
references.citation: Thyroid. 2003 Mar;13(3):265-71
references.pmid: 12729475
references.citation: Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):535-40
references.pmid: 8655377
references.citation: Physiol Rev. 2000 Jul;80(3):1083-105
references.pmid: 10893432
references.citation: Head Neck. 2011 May;33(5):686-90
references.pmid: 21484917
references.citation: Clin Endocrinol (Oxf). 2005 Oct;63(4):418-27
references.pmid: 16181234
references.citation: Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1428-32
references.pmid: 12397459
references.citation: Clin Nucl Med. 1989 Apr;14(4):301-2
references.pmid: 2706876
references.citation: Eur J Endocrinol. 2006 Oct;155(4):495-512
references.pmid: 16990649
references.citation: J Clin Endocrinol Metab. 1998 May;83(5):1746-51
references.pmid: 9589686
references.citation: Clin Nucl Med. 1990 Sep;15(9):610-1
references.pmid: 2119928
references.citation: J Nucl Med. 1998 Sep;39(9):1551-4
references.pmid: 9744341
references.citation: Otolaryngol Head Neck Surg. 2013 May;148(5):746-52
references.pmid: 23462656
references.citation: Clin Nucl Med. 1992 Feb;17(2):130-1
references.pmid: 1563183
references.citation: Thyroid. 2004 Feb;14(2):133-40
references.pmid: 15068628
references.citation: Clin Nucl Med. 1995 Oct;20(10):876-7
references.pmid: 8616990
references.citation: J Nucl Med. 1986 Oct;27(10):1519-27
references.pmid: 3760975
references.citation: Ear Nose Throat J. 2000 Jun;79(6):460-8
references.pmid: 10893838
references.citation: Am J Roentgenol Radium Ther Nucl Med. 1966 Mar;96(3):593-5
references.pmid: 5904870
references.citation: Rev Endocr Metab Disord. 2000 Apr;1(3):205-15
references.pmid: 11705005
references.citation: Thyroid. 2001 May;11(5):415-25
references.pmid: 11396700
references.citation: J Clin Endocrinol Metab. 2002 Dec;87(12):5817-20
references.pmid: 12466391
references.citation: Biochim Biophys Acta. 1993 Jun 8;1154(1):65-82
references.pmid: 8507647
references.citation: Thyroid. 2013 May;23(5):609-16
references.pmid: 23153322
references.citation: Histochemistry. 1982;74(4):585-8
references.pmid: 7107332
references.citation: Semin Nucl Med. 2000 Apr;30(2):115-32
references.pmid: 10787192
references.citation: Endocr Rev. 2003 Feb;24(1):48-77
references.pmid: 12588808
references.citation: Clin Nucl Med. 2005 Aug;30(8):543-5
references.pmid: 16024949
references.citation: Clin Nucl Med. 2002 Nov;27(11):767-71
references.pmid: 12394122
references.citation: Int Forum Allergy Rhinol. 2013 Oct;3(10):841-7
references.pmid: 23901007
references.citation: Thyroid. 2014 Mar;24(3):472-9
references.pmid: 23937391
references.citation: Thyroid. 2006 Dec;16(12):1229-42
references.pmid: 17199433
references.citation: Ophthalmic Plast Reconstr Surg. 2004 Mar;20(2):126-9
references.pmid: 15083081
references.citation: J Nucl Med. 1990 Jan;31(1):52-4
references.pmid: 2295940
references.citation: Nucl Med Commun. 2000 Oct;21(10):955-7
references.pmid: 11130337
references.citation: J Nucl Med. 2001 May;42(5):738-43
references.pmid: 11337569
references.citation: J Oral Maxillofac Surg. 1999 Jun;57(6):738-41
references.pmid: 10368102
references.citation: Oral Surg Oral Med Oral Pathol. 1993 Mar;75(3):312-7
references.pmid: 8469541
references.citation: J Nucl Med. 1998 Aug;39(8):1452-4
references.pmid: 9708527
references.citation: J Nucl Med. 2008 Nov;49(11):1776-82
references.pmid: 18927337